CGEM - Cullinan Therapeutics Announces Positive End-of- Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrat
CGEM - Cullinan Therapeutics Announces Positive End-of- Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML